Skip to main content
    C

    Contineum Therapeutics, Inc. Class A Common Stock (CTNM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.67
    -0.19 (-1.93%)

    Market Cap: $387.16M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Contineum Therapeutics, Inc. Class A Common Stock (CTNM) to earn -$1.78 per share in the fiscal year ending Dec 31, 2026. Of 8 analysts, 6 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 2 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 8 ratings average 2.13, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 75% of the ratings.

    RatingAnalystsShare
    Strong Buy112.5%
    Buy562.5%
    Hold225.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    8

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a larger loss.

    Fiscal year ending Dec 31, 2026
    -$1.78
    EPS consensus
    Fiscal year ending Dec 31, 2027
    -$2.05
    EPS consensus
    Next report
    Mar 3, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$1.78-$1.83 to -$1.727
    Dec 31, 2027-$2.05-$2.49 to -$1.647

    Quarterly Estimates

    The EPS consensus rises from -$0.50 for the quarter ending Dec 31, 2026 to -$0.47 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$0.50-$0.54 to -$0.3510
    Mar 31, 2027-$0.47-$0.54 to -$0.393

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 4 upward and 6 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202612
    Fiscal year ending Dec 31, 202714
    Quarter ending Mar 31, 202720

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$1.56.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$1.78-$1.70-$1.71-$1.56-$1.56N/A
    Fiscal year ending Dec 31, 2027-$2.05-$1.93-$1.92-$1.80-$1.82N/A
    Quarter ending Mar 31, 2027-$0.47-$0.43-$0.45-$0.46-$0.46N/A

    Frequently Asked Questions About CTNM

    What is the CTNM stock forecast?

    Consensus analyst estimates put Contineum Therapeutics, Inc. Class A Common Stock's EPS at -$1.78 for the fiscal year ending Dec 31, 2026. The consensus rating from 8 analysts is Buy.

    How do analysts rate CTNM stock?

    Of 8 analysts covering Contineum Therapeutics, Inc. Class A Common Stock, 1 rates it Strong Buy, 5 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from CTNM next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.78, with estimates from -$1.83 to -$1.72 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.05, with estimates from -$2.49 to -$1.64 from 7 analysts.

    How many analysts cover CTNM?

    8 analysts rate Contineum Therapeutics, Inc. Class A Common Stock stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.